Ticlopidine activity on platelet function in patients with enhanced platelet aggregation. A short-term crossover study

G. F. Gensini, S. Favilla, C. Breschi, R. Abbate, G. Costanzo, G. G. Neri Serneri

Research output: Contribution to journalArticle

Abstract

In a single-blind crossover study, the effect of ticlopidine (250 mg t.i.d.) on platelet function was investigated in 16 patients, with enhanced platelet aggregation, before treatment, on the third and seventh day of treatment with the drug or the placebo. Bleeding time was significantly lengthened by ticlopidine administration. Platelet aggregation, both in vivo and in vitro, was significantly inhibited during the week on ticlopidine. Beta-thromboglobulin concentration was on an average significantly decreased. The inhibition by PGI2 of platelet aggregation was significantly enhanced during treatment, whereas the inhibition of platelet aggregation by PGD2 was slightly but not significantly increased. Platelet TxB2 production after stimulation with thrombin was unchanged during ticlopidine administration, whereas conversion of exogenous arachidonic acid into TxB2 was slightly but significantly reduced. The present results confirm that ticlopidine acts in vivo as a powerful antiaggregating agent. The antiaggregating activity seems to be due to an interference of ticlopidine with platelet membrane and, as a consequence, with various platelet membrane receptors and activities.

Original languageEnglish
Pages (from-to)294-300
Number of pages7
JournalHaemostasis
Volume13
Issue number5
Publication statusPublished - 1983

Fingerprint

Ticlopidine
Platelet Aggregation
Cross-Over Studies
Blood Platelets
beta-Thromboglobulin
Single-Blind Method
Prostaglandin D2
Bleeding Time
Membranes
Epoprostenol
Arachidonic Acid
Thrombin
Therapeutics
Placebos
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Hematology

Cite this

Gensini, G. F., Favilla, S., Breschi, C., Abbate, R., Costanzo, G., & Neri Serneri, G. G. (1983). Ticlopidine activity on platelet function in patients with enhanced platelet aggregation. A short-term crossover study. Haemostasis, 13(5), 294-300.

Ticlopidine activity on platelet function in patients with enhanced platelet aggregation. A short-term crossover study. / Gensini, G. F.; Favilla, S.; Breschi, C.; Abbate, R.; Costanzo, G.; Neri Serneri, G. G.

In: Haemostasis, Vol. 13, No. 5, 1983, p. 294-300.

Research output: Contribution to journalArticle

Gensini, GF, Favilla, S, Breschi, C, Abbate, R, Costanzo, G & Neri Serneri, GG 1983, 'Ticlopidine activity on platelet function in patients with enhanced platelet aggregation. A short-term crossover study', Haemostasis, vol. 13, no. 5, pp. 294-300.
Gensini GF, Favilla S, Breschi C, Abbate R, Costanzo G, Neri Serneri GG. Ticlopidine activity on platelet function in patients with enhanced platelet aggregation. A short-term crossover study. Haemostasis. 1983;13(5):294-300.
Gensini, G. F. ; Favilla, S. ; Breschi, C. ; Abbate, R. ; Costanzo, G. ; Neri Serneri, G. G. / Ticlopidine activity on platelet function in patients with enhanced platelet aggregation. A short-term crossover study. In: Haemostasis. 1983 ; Vol. 13, No. 5. pp. 294-300.
@article{4852b9a12e884edab1557c0e8ebba468,
title = "Ticlopidine activity on platelet function in patients with enhanced platelet aggregation. A short-term crossover study",
abstract = "In a single-blind crossover study, the effect of ticlopidine (250 mg t.i.d.) on platelet function was investigated in 16 patients, with enhanced platelet aggregation, before treatment, on the third and seventh day of treatment with the drug or the placebo. Bleeding time was significantly lengthened by ticlopidine administration. Platelet aggregation, both in vivo and in vitro, was significantly inhibited during the week on ticlopidine. Beta-thromboglobulin concentration was on an average significantly decreased. The inhibition by PGI2 of platelet aggregation was significantly enhanced during treatment, whereas the inhibition of platelet aggregation by PGD2 was slightly but not significantly increased. Platelet TxB2 production after stimulation with thrombin was unchanged during ticlopidine administration, whereas conversion of exogenous arachidonic acid into TxB2 was slightly but significantly reduced. The present results confirm that ticlopidine acts in vivo as a powerful antiaggregating agent. The antiaggregating activity seems to be due to an interference of ticlopidine with platelet membrane and, as a consequence, with various platelet membrane receptors and activities.",
author = "Gensini, {G. F.} and S. Favilla and C. Breschi and R. Abbate and G. Costanzo and {Neri Serneri}, {G. G.}",
year = "1983",
language = "English",
volume = "13",
pages = "294--300",
journal = "Haemostasis",
issn = "0301-0147",
publisher = "S. Karger AG",
number = "5",

}

TY - JOUR

T1 - Ticlopidine activity on platelet function in patients with enhanced platelet aggregation. A short-term crossover study

AU - Gensini, G. F.

AU - Favilla, S.

AU - Breschi, C.

AU - Abbate, R.

AU - Costanzo, G.

AU - Neri Serneri, G. G.

PY - 1983

Y1 - 1983

N2 - In a single-blind crossover study, the effect of ticlopidine (250 mg t.i.d.) on platelet function was investigated in 16 patients, with enhanced platelet aggregation, before treatment, on the third and seventh day of treatment with the drug or the placebo. Bleeding time was significantly lengthened by ticlopidine administration. Platelet aggregation, both in vivo and in vitro, was significantly inhibited during the week on ticlopidine. Beta-thromboglobulin concentration was on an average significantly decreased. The inhibition by PGI2 of platelet aggregation was significantly enhanced during treatment, whereas the inhibition of platelet aggregation by PGD2 was slightly but not significantly increased. Platelet TxB2 production after stimulation with thrombin was unchanged during ticlopidine administration, whereas conversion of exogenous arachidonic acid into TxB2 was slightly but significantly reduced. The present results confirm that ticlopidine acts in vivo as a powerful antiaggregating agent. The antiaggregating activity seems to be due to an interference of ticlopidine with platelet membrane and, as a consequence, with various platelet membrane receptors and activities.

AB - In a single-blind crossover study, the effect of ticlopidine (250 mg t.i.d.) on platelet function was investigated in 16 patients, with enhanced platelet aggregation, before treatment, on the third and seventh day of treatment with the drug or the placebo. Bleeding time was significantly lengthened by ticlopidine administration. Platelet aggregation, both in vivo and in vitro, was significantly inhibited during the week on ticlopidine. Beta-thromboglobulin concentration was on an average significantly decreased. The inhibition by PGI2 of platelet aggregation was significantly enhanced during treatment, whereas the inhibition of platelet aggregation by PGD2 was slightly but not significantly increased. Platelet TxB2 production after stimulation with thrombin was unchanged during ticlopidine administration, whereas conversion of exogenous arachidonic acid into TxB2 was slightly but significantly reduced. The present results confirm that ticlopidine acts in vivo as a powerful antiaggregating agent. The antiaggregating activity seems to be due to an interference of ticlopidine with platelet membrane and, as a consequence, with various platelet membrane receptors and activities.

UR - http://www.scopus.com/inward/record.url?scp=0021054094&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021054094&partnerID=8YFLogxK

M3 - Article

C2 - 6228500

AN - SCOPUS:0021054094

VL - 13

SP - 294

EP - 300

JO - Haemostasis

JF - Haemostasis

SN - 0301-0147

IS - 5

ER -